Featured Research

from universities, journals, and other organizations

Drug prevents bone loss side effects of breast cancer medication

Date:
October 10, 2011
Source:
Wiley-Blackwell
Summary:
A new study has found that an osteoporosis drug protects against the bone damaging side effects of certain breast cancer medications. The study indicates that some breast cancer patients could take zoledronic acid in addition to their anti-cancer medications to maintain bone health.

A new study has found that an osteoporosis drug protects against the bone damaging side effects of certain breast cancer medications. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that some breast cancer patients could take zoledronic acid in addition to their anti-cancer medications to maintain bone health.

Related Articles


Drugs called aromatase inhibitors stop the production of estrogen in postmenopausal women and therefore make less estrogen available to stimulate the growth of certain breast cancer cells. Many postmenopausal women with breast cancer are routinely treated for several years with these potentially life-saving drugs, but the agents can cause bone loss and fractures.

Adam Brufsky, MD, PhD, of the University of Pittsburgh Cancer Institute, and his colleagues conducted a study to see if the bone drug zoledronic acid could prevent and treat bone loss in postmenopausal breast cancer patients. In their five-year study, called Z-FAST, 602 postmenopausal women with early breast cancer who were receiving the aromatase inhibitor letrozole were randomized to receive zoledronic acid simultaneously with letrozole or only after bone loss or fractures occurred.

The investigators observed significant and progressive increases in bone density throughout the five years of the study in women who initiated zoledronic acid at the start; in contrast, significant decreases in bone density occurred when zoledronic acid administration was delayed until bone loss was apparent. Over time, though, the rate of bone density decline in the delayed group slowed, most likely because more delayed patients received zoledronic acid by the end of the study. These findings indicate that bone density is maintained more effectively with upfront zoledronic acid, but bone loss is likely reversible so that initiating zoledronic acid, even after bone loss has developed, is beneficial.

"This study shows that bone loss from aromatase inhibitors can be prevented long term with a safe and effective drug that prevents osteoporosis," said Dr. Brufsky. Zoledronic acid is currently approved by the U.S. Food and Drug Administration for conditions including osteoporosis and bone complications of cancer.


Story Source:

The above story is based on materials provided by Wiley-Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Adam M. Brufsky, W. Graydon Harker, J. Thaddeus Beck, Linda Bosserman, Charles Vogel, Christopher Seidler, Lixian Jin, Ghulam Warsi, Eliza Argonza-Aviles, John Hohneker, Solveig G. Ericson, Edith A. Perez. Final 5-year results of Z-FAST trial Adjuvant Zoledronic Acid Maintains Bone Mass in Postmenopausal Breast Cancer Patients Receiving Letrozole. Cancer, 2011; DOI: 10.1002/cncr.26313

Cite This Page:

Wiley-Blackwell. "Drug prevents bone loss side effects of breast cancer medication." ScienceDaily. ScienceDaily, 10 October 2011. <www.sciencedaily.com/releases/2011/10/111010075526.htm>.
Wiley-Blackwell. (2011, October 10). Drug prevents bone loss side effects of breast cancer medication. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2011/10/111010075526.htm
Wiley-Blackwell. "Drug prevents bone loss side effects of breast cancer medication." ScienceDaily. www.sciencedaily.com/releases/2011/10/111010075526.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com
Doctor in NYC Quarantined With Ebola

Doctor in NYC Quarantined With Ebola

AP (Oct. 24, 2014) An emergency room doctor who recently returned to the city after treating Ebola patients in West Africa has tested positive for the virus. He's quarantined in a hospital. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins